Search

Kathy Hart - uterine cancer recovery

Kathy Hart - uterine cancer recovery

June 12, 2024

Kathy Hart is on the path to recovery following a rare skin and musculature condition that ultimately revealed stage 3 uterine cancer. She has a good prognosis with the benefit of complex, multidisciplinary care at OHSU. (OHSU/Christine Torres Hicks)

OHSU patient Kathy Hart on the mend

OHSU patient Kathy Hart on the mend

June 12, 2024

Kathy Hart is on the path to recovery following a rare skin and musculature condition that ultimately revealed stage 3 uterine cancer. She has a good prognosis with the benefit of complex, multidisciplinary care at OHSU. (OHSU/Christine Torres Hicks)

Klaus Früh, Ph.D.

Klaus Früh, Ph.D.

May 31, 2024

Klaus Früh, Ph.D., professor in OHSU’s Vaccine & Gene Therapy Institute, investigates the potential of cytomegalovirus-based vaccines. With colleagues Louis Picker, M.D., and Scott Hansen, Ph.D., both in VGTI, they have found their vaccine platform shows promise as a “shield” against cancer. (OHSU/Christine Torres Hicks)

Louis Picker, M.D.

Louis Picker, M.D.

May 31, 2024

Louis Picker, M.D., professor in OHSU’s Vaccine & Gene Therapy Institute, investigates the potential of cytomegalovirus-based vaccines. With colleagues Klaus Früh, Ph.D., and Scott Hansen, Ph.D., both in VGTI, they have found their vaccine platform shows promise as a “shield” against cancer.

A 'shield' against cancer

A 'shield' against cancer

May 31, 2024

In a new study, Klaus Früh, Ph.D., left, Louis Picker, M.D., and Scott Hansen, Ph.D., all in OHSU’s Vaccine & Gene Therapy Institute, show that their platform for cytomegalovirus-based vaccines shows promise as a “shield” against cancer. (OHSU/Christine Torres Hicks)

See More Stories